The authors review the current regulatory framework for the selection of drug substance starting materials.
Linda Billett
Advertisement
Linda Billett is a CMC director of global regulatory affairs at AstraZeneca (Macclesfield).
Articles by Linda Billett
Advertisement
Latest Updated Articles
Drug Substance Starting Material SelectionPublished: December 2nd 2008 | Updated:
Advertisement
Advertisement
